Infantile hemangiomas with unusually prolonged growth phase: a case series

Arch Dermatol. 2008 Dec;144(12):1632-7. doi: 10.1001/archderm.144.12.1632.

Abstract

Background: Most infantile hemangiomas (IHs) complete their proliferative growth phase before 9 months of age, but those with unusually prolonged growth create unique clinical challenges. We performed a retrospective case series of IHs with prolonged growth to further characterize these lesions and their treatment.

Observations: We identified 23 patients as having IHs with prolonged growth after 9 months of age, with growth to a mean age of 17 months. All of the IHs had a deep dermal to subcutaneous component, all had either segmental or indeterminate morphologic characteristics, and 39% involved the parotid gland. A total of 20 of 23 received prolonged treatment with systemic corticosteroids (mean duration of treatment, 11 months), and 9 of 20 received additional systemic therapies (vincristine sulfate and/or interferon alfa-2a or alfa-2b).

Conclusions: Prolonged growth was observed primarily in IHs with a deep component and segmental morphologic characteristics. Recognition of this subset of hemangiomas is important for clinicians, and further study of IHs may provide clues to their pathogenesis.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Age Factors
  • Child, Preschool
  • Disease Progression
  • Hemangioma / drug therapy*
  • Hemangioma / pathology*
  • Humans
  • Infant
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Interferons / therapeutic use
  • Recombinant Proteins
  • Retrospective Studies
  • Vincristine / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Vincristine
  • Interferons